Results 131 to 140 of about 4,954 (216)

CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas. [PDF]

Leukemia
Babin L, Andraos E, Fuchs S, Bessière C, Colras L, Dailhau S, Quelen C, Pinto C, Daoudi I, Pfeifer R, Zamani A, Bousquet M, Pyronnet S, Gaspin C, Lamant L, Meggetto F.   +15 more
europepmc   +1 more source

Matching circadian rhythms to light-dark cycles increases lettuce yield by 29% in vertical farms without additional energy input. [PDF]

J Exp Bot
Anton-Sales C, Benckhuysen L, Peker B, Jeuken M, Bonnema G.   +4 more
europepmc   +1 more source

CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas. [PDF]

Sci Rep
Andraos E, Fuchs S, Bessière C, Colras L, Dailhau S, Bousquet M, Touzart A, Lhermitte L, Gaspin C, Pyronnet S, Lamant L, Meggetto F, Babin L.   +12 more
europepmc   +1 more source

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study. [PDF]

Neurol Ther
Barbanti P, Aurilia C, Filippi M, Doretti A, d'Onofrio F, Scatena P, Vecchio R, Messina R, Vinciguerra L, Ranieri A, Baldisseri F, Torelli P, Russo M, Cutrona C, Viticchi G, Egeo G, Autunno M, Pistoia F, Finocchi C, Camarda C, Messina S, Rinalduzzi S, Drago V, Caputi L, Bandettini di Poggio M, Quintana S, Salerno A, Bartolini M, Fiorentini G, Spieckert de Souza J, Di Stani F, Bonassi S, Porreca A, Italian Migraine Registry Study Group.   +33 more
europepmc   +1 more source

Genome-wide association analysis of treatment response to onabotulinumtoxinA in Han Chinese patients with chronic migraine: a pilot study. [PDF]

BMC Neurol
An YC, Liang CS, Tsai CK, Tsai CL, Lin YK, Liao WI, Yeh PK, Lin GY, Hsieh CH, Hung KS, Yang FC.   +10 more
europepmc   +1 more source

Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study. [PDF]

J Neurol
Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d'Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S, Italian Migraine Registry (I-GRAINE) study group.   +14 more
europepmc   +1 more source

A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II). [PDF]

J Neurol
Barbanti P, Aurilia C, Egeo G, Doretti A, d'Onofrio F, Scatena P, Rinalduzzi S, Vinciguerra L, Sansone M, Vecchio R, Drago V, Viticchi G, Bartolini M, Ranieri A, Bandettini di Poggio M, Baldisseri F, Mascarella D, Brusaferri F, Caputi L, Messina S, Autunno M, Valenza A, Orlando B, Distefano M, Borrello L, Pistoia F, Camarda C, Saporito G, Querzola G, Torelli P, Salerno A, Gragnani F, Petolicchio B, Carnevale A, Messina R, Filippi M, Tavani S, Fiorentini G, Bonassi S, Cevoli S, Mannocci A, Italian Migraine Registry (I-GRAINE) study group.   +41 more
europepmc   +1 more source

P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease. [PDF]

JCI Insight
Duparc T, Gore E, Combes G, Beuzelin D, Pires Da Silva J, Bouguetoch V, Marquès MA, Velazquez A, Viguerie N, Tavernier G, Arner P, Rydén M, Langin D, Sioufi N, Nasser M, Cabou C, Najib S, Martinez LO.   +17 more
europepmc   +1 more source

Impatto clinico ed economico dell’emicrania in Italia: un’analisi di real-world evidence. [PDF]

Glob Reg Health Technol Assess
Perrone V, Leonetti S, Esposti LD, Giannessi L, Guerzoni S, Entities group.   +5 more
europepmc   +1 more source